犬淋巴瘤預後與CD10、Bcl-6、MUM1和Bcl-2表現之相關性

Abstract

Lymphoma is one of the most common malignancies in dogs. Canine lymphoma bears a morphological resemblance to non-Hodgkin’s lymphoma in the human. Diffuse large B-cell lymphoma (DLBCL), according to the World Health Organization (WHO) classification, is the most common form of canine lymphoma. Furthermore, indolent lymphomas that are characterized by a slowly progressive clinical course include follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and T-zone lymphoma. Human DLBCLs can be sorted into two molecular subtypes: germinal center B-cell-like (GCB) DLBCL and activated B-cell-like (ABC) DLBCL. CD10 and Bcl-6 are biomarkers for GCB-DLBCL, while ABC-DLBCL is representative of MUM1 or Bcl-2 expression. Patients diagnosed with GCB-DLBCL show a significant better overall survival rate than those diagnosed with ABC-DLBCL. The present study is to investigate the correlation between prognosis and expression of CD10, Bcl-6, MUM1 and Bcl-2 in canine lymphomas. A total of 102 cases met the inclusion criteria, with 59 of B-cell derivation, 41 of T-cell derivation, and 2 of null-cell derivation. DLBCL was the most common diagnosis based on the WHO criteria. Immunohistochemical stain for CD10, Bcl-6, MUM1 and Bcl-2 was performed on a total of 53 cases with a complete medical and follow-up record. The results indicated that none of the markers had a correlation with prognosis with the exception of Bcl-2. Bcl-2 expression had a significantly positive correlation with overall survival time. Moreover, indolent lymphomas not only showed prolonged overall survival over non-indolent lymphomas, but also were characterized by moderate or strong levels of Bcl-2 expression. In conclusion, we did not find molecular subtypes of canine DLBCL via CD10, Bcl-6, MUM1 and Bcl-2 expression. Among these four markers, only Bcl-2 had a potential prognostic value of canine lymphomas. The mechanism of Bcl-2 remains to be determined, though.